reconstitution comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-16. Numbers and descriptions here follow the published literature rather than marketing material.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Peptides are short chains of amino acids linked by amide bonds, and their storage stability depends on sequence, length, and three-dimensional structure. Chemical degradation can occur through hydrolysis, oxidation, deamidation, and aggregation, while physical changes such as precipitation or surface adsorption reduce recovery. Storage conditions are chosen to slow these processes without altering the peptide itself. Because peptides vary widely, no single condition suits every sequence, so laboratories often establish stability empirically for each batch.
Temperature is a primary factor because most degradation reactions proceed more slowly at lower temperatures. Lyophilized peptides are commonly held at -20 °C or below, although some sequences remain stable at 2–8 °C for limited periods. Moisture uptake during handling can accelerate hydrolysis, so sealed containers and desiccants are used. Solutions are generally less stable than powders and may require freezing at -80 °C or refrigeration, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation even when the storage temperature is otherwise suitable.
Light, oxygen, and pH influence peptide integrity through specific side-chain reactions. Methionine and cysteine residues are susceptible to oxidation, and tryptophan can degrade under strong light. Inert gas overlays and amber glass or opaque containers reduce these risks. pH affects charge, solubility, and the rate of deamidation or aggregation; a value that minimizes one pathway may increase another. The optimal pH and buffer for a given peptide are often determined experimentally, and open questions remain about predicting stability from sequence alone.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (lyophilized) | -20°C | Stable for months to years; avoid frost-free freezers |
| Storage temperature (solution) | -80°C | Single-use aliquots preferred; avoid repeated freeze-thaw |
| Reconstitution solvent | Sterile water or buffer | Choice depends on peptide solubility and application |
| Container material | Glass or polypropylene | Low protein-binding surfaces reduce adsorption |
| Shipping condition | Dry ice | Insulated packaging maintains cold chain during transit |
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Container and environment choices matter. Peptides may adsorb to glass, plastic, or filter membranes, especially at low concentrations. Low-binding tubes and inert containers reduce loss. Moisture barriers include sealed bags with desiccant, and light protection uses amber vials or opaque wraps. Inert gas blankets can limit oxidation for sequences containing methionine, cysteine, or tryptophan. Buffers and pH also affect solution stability; extremes of pH accelerate hydrolysis and deamidation. These practices apply to research and manufacturing settings, not to any specific clinical use.
Peptides are short amino acid polymers whose stability depends on sequence, length, and chemical modifications. In dry form, most peptides are relatively stable because low water activity slows hydrolysis and other degradation. Residual moisture, oxygen, and light can still promote oxidation, deamidation, or aggregation over time. Storage recommendations therefore usually combine low temperature, desiccation, and protection from light. Because each peptide has distinct properties, no single condition fits every sequence.
Temperature selection balances degradation rate against physical changes. Many lyophilized peptides are stored at -20 °C, while some modified or longer sequences require -80 °C for extended periods. Aqueous stock solutions are less stable and are often kept at -20 °C or below in single-use aliquots. Repeated freeze-thaw cycles can cause aggregation, precipitation, or loss of activity, so aliquoting before freezing reduces that risk. Frost-free freezers cycle above freezing and may be unsuitable for long-term peptide storage.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
Bilirubin in plasma is mostly produced by the destruction of erythrocytes. Heme is metabolized into biliverdin (via heme oxygenase) and then into bilirubin (via biliverdin reductase) inside the macrophages. Bilirubin is then released into the plasma and transported to the liver bound by albumin, since it is insoluble in water in this state. In this state, bilirubin is called unconjugated (despite being bound by albumin). In the liver, unconjugated (indirect) bilirubin is up-taken by the hepatocytes and subsequently conjugated with glucuronic acid (via the enzyme uridine diphosphate–glucuronyl transferase). In this state, bilirubin is soluble in water and it is called conjugated bilirubin. Conjugated (direct) bilirubin is excreted into the bile ducts and enters the duodenum. During its transport to the colon, it is converted into urobilinogen by the bacterial enzyme bilirubin reductase. Most of the urobilinogen is further reduced into stercobilinogen and is excreted through feces (air oxidizes stercobilinogen to stercobilin, which gives feces their characteristic brown color). A lesser amount of urobilinogen is re-absorbed into portal circulation and transferred to the liver. For the most part, this urobilinogen is recycled to conjugated bilirubin and this process closes the enterohepatic circle. There is also an amount of urobilinogen which is not recycled, but rather enters the systemic circulation and subsequently the kidneys, where it is excreted. Air oxidizes urobilinogen into urobilin, which gives urine its characteristic color.
=== Early 2007: Deaths in younger populations === The first middle-school "cheese" death in published accounts was that of Oscar Gutierrez, a 15-year-old eighth grader in northwest Dallas, who died February 18, 2007; his brother stated that the boy had previously survived an overdose of the same drug. Community rallies followed Gutierrez' death as parents and others urged the police and school district to become more active in fighting what was viewed as a growing problem. The death of Fernando Cortez Jr., a high school student, on March 31, 2007, led to further community activism. Initially this death was linked to cheese heroin based on the father's comments in press reports; the father said his son was at a Corvallis party when he was offered "cheese" and that the boy had not tried drugs before that he was aware of. Cortez's father went on to become a speaker at community meetings within the school system, urging that parents keep closer watch over their children. On April 24, the same day toxicology results were announced confirming the link to cheese, police announced a family friend would be charged with murder for having mixed the drugs for Cortez.
== Adverse effects == During the treatment some patients may develop some adverse effects predominantly of the skin and subcutaneous tissue: burning and itching (in absolute the most common side effect), contact dermatitis, dryness and skin irritation.
Sources: en.wikipedia.org
==== Determining hydrogen storage capacity ==== Two hydrogen-uptake measurement methods are used for the characterization of MOFs as hydrogen storage materials: gravimetric and volumetric. To obtain the total amount of hydrogen in the MOF, both the amount of hydrogen absorbed on its surface and the amount of hydrogen residing in its pores should be considered. To calculate the absolute absorbed amount (Nabs), the surface excess amount (Nex) is added to the product of the bulk density of hydrogen (ρbulk) and the pore volume of the MOF (Vpore), as shown in the following equation:
== Calculation == As noted before, DIAAS considers the digestibility of individual essential amino acids (EAAs). The amounts of each amino acid in the test food and in the digested mixture at the end of the small intestine is subtracted to give the absorbed amount of each EAA ai. The value is divided by the total amount of protein in the test food to give the milligrams of each EAA absorbed for each gram of the protein Ai. One then looks up the desired reference pattern, which gives the amount of an EAA in 1 gram of the "reference protein" Ri. For each EAA, the "reference ratio" Ai/Ri is calculated. The final DIAAS is 100% times the lowest reference ratio. Amino acid digestibility is preferably scored using humans. If humans are not available, determination in growing pigs or growing rats are acceptable. For measurement in humans, a minimally invasive dual-tracer method has been developed for the DIAAS method.
=== Mandatory spending and social safety nets === Social Security, Medicare, and Medicaid expenditures are funded by more permanent Congressional appropriations and so are considered mandatory spending. Social Security and Medicare are sometimes called "entitlements", because people meeting relevant eligibility requirements are legally entitled to benefits; most pay taxes into these programs throughout their working lives. Some programs, such as Food Stamps, are appropriated entitlements. Some mandatory spending, such as Congressional salaries, is not part of any entitlement program. Mandatory spending accounted for 59.8% of total federal outlays (net of receipts that partially pay for the programs), with net interest payments accounting for an additional 6.5%. In 2000, these were 53.2% and 12.5%, respectively. Mandatory spending is expected to continue increasing as a share of GDP. This is due in part to demographic trends, as the number of workers continues declining relative to those receiving benefits. For example, the number of workers per retiree was 5.1 in 1960; this declined to 3.0 in 2010 and is projected to decline to 2.2 by 2030. These programs are also affected by per-person costs, which are also expected to increase at a rate significantly higher than economic growth. This unfavorable combination of demographics and per-capita rate increases is expected to drive both Social Security and Medicare into large deficits during the 21st century.
=== Mechanism of action === Miconazole inhibits the fungal enzyme 14α-sterol demethylase, resulting in a reduced production of ergosterol. In addition to its antifungal actions, miconazole, similarly to ketoconazole, is known to act as an antagonist of the glucocorticoid receptor. Miconazole is also known to bind to tubulin and inhibit its polymerization. Miconazole inhibits CYP2J2.
Sources: en.wikipedia.org
==== 2011–2018: Rebuilding, return of trophies, and departure ==== Wenger's preparations for the 2011–12 season were disrupted by player unrest. Though he insisted none of his top players would leave the club, Fàbregas eventually moved to Barcelona, while Gaël Clichy and Samir Nasri joined Manchester City. Suspensions and injuries left Wenger fielding an understrength side against Manchester United on 29 August 2011; Arsenal were trounced 8–2, which represented their worst defeat in 115 years. Needing to address the squad's lack of depth, Wenger completed a series of deals in the final days of the summer transfer window. He mostly brought in experienced players, such as Yossi Benayoun on loan from Chelsea, Everton's Mikel Arteta and Germany international Per Mertesacker. By October, Arsenal had made their worst start to a season in 58 years, losing four of their opening seven matches. However, the team soon harmonised and, in the same month, club captain Robin van Persie scored a hat-trick as Arsenal beat Chelsea 5–3. Despite another season of no silverware, Wenger guided Arsenal to third position in the Premier League, thus qualifying for the Champions League for a 15th successive campaign. Van Persie had scored 37 goals, in his first injury-free season for the club. He, however, grew disillusioned with Arsenal's transfer policy, and decided not to renew his contract, with one year remaining. When Manchester United manager Sir Alex Ferguson learnt of the situation, he called Wenger to push through a deal and Van Persie agreed to join Manchester United in August 2012.
=== Industries and economic zones === Ningxia was a major recipient of China's investment in industrial capacity during the Third Front campaign. Yinchuan Economic and Technological Development Zone was established in 1992. Spanning 32 km2 (12 sq mi), it has an annual economic output Rmb23.7 billion (25.1% up) (US$3.5 billion). Major investors are mainly local enterprises such as Kocel Steel Foundry, FAG Railway Bearing (Ningxia), Ningxia Little Giant Machine Tools, etc. Major industries include machinery and equipment manufacturing, new materials, fine chemicals and the animation industry. Desheng Industrial Park (in Helan County) is a base for about 400 enterprises. The industrial park has industrial chains from Muslim food and commodities to trade and logistics, new materials and bio-pharmaceuticals that has 80 billion yuan in fixed assets. Desheng is looking to be the most promising industrial park in the city. It achieved a total output value of 4.85 billion in 2008, up 40 percent year-on-year. The local government plans to cut taxes and other fees to reduce the burden on local enterprises. The industrial output value reached 2.68 billion yuan in 2008, an increase of 48 percent from a year earlier.
== Human proteins == The human mitochondrial rhodanese gene is TST. The following other human genes match the "Rhodanese-like" domain on InterPro, but are not the rodanase with its catalytic activity (see also the list of related families in #Structure and mechanism):
=== Synthesis === Synthesis of RNA typically occurs in the cell nucleus and is usually catalyzed by an enzyme—RNA polymerase—using DNA as a template, a process known as transcription. Initiation of transcription begins with the binding of the enzyme to a promoter sequence in the DNA (usually found "upstream" of a gene). The DNA double helix is unwound by the helicase activity of the enzyme. The enzyme then progresses along the template strand in the 3' to 5' direction, synthesizing a complementary RNA molecule with elongation occurring in the 5' to 3' direction. The DNA sequence also dictates where termination of RNA synthesis will occur. Primary transcript RNAs are often modified by enzymes after transcription. For example, a poly(A) tail and a 5' cap are added to eukaryotic pre-mRNA and introns are removed by the spliceosome. There are also a number of RNA-dependent RNA polymerases that use RNA as their template for synthesis of a new strand of RNA. For instance, a number of RNA viruses (such as poliovirus) use this type of enzyme to replicate their genetic material. Also, RNA-dependent RNA polymerase is part of the RNA interference pathway in many organisms.
Northern: The northern section runs from the Canadian province of Newfoundland and Labrador to the Hudson River. It includes the Long Range Mountains and Annieopsquotch Mountains on the island of Newfoundland, the French Territorial Collectivity of Saint-Pierre and Miquelon southwest of Newfoundland, Chic-Choc Mountains and Notre Dame Range in Quebec and New Brunswick, scattered elevations and small ranges elsewhere in Nova Scotia and New Brunswick, the Longfellow Mountains in Maine, the White Mountains in New Hampshire, the Green Mountains in Vermont, and The Berkshires in Massachusetts, and Connecticut, the Metacomet Ridge Mountains in Connecticut and south-central Massachusetts, and the Adirondack Mountains in New York are all part of the Appalachian Mountains as defined by the governments of Canada and the United States.Mountains of the Long Range in Newfoundland, such as the Cabox and Gros Morne, reach heights of nearly 2,700 ft (800 m). In the Chic-Choc and Notre Dame Mountain ranges in Quebec, the higher summits rise above 4,000 ft (1,200 m) in elevation. Isolated peaks and small ranges in Nova Scotia and New Brunswick vary from 1,000 to 2,700 ft (300 to 800 m). In Maine, several peaks exceed 4,000 ft (1,200 m), including Mount Katahdin at 5,267 feet (1,605 m).
Sources: en.wikipedia.org
Common solvents include sterile water, phosphate-buffered saline, and water-acetonitrile mixtures. The choice depends on the peptide's solubility profile and the buffer compatibility for the intended application. Manufacturers often provide a recommended solvent on the product information sheet.
Solutions are typically stored at -80°C in single-use aliquots to avoid repeated freeze-thaw cycles. They should be protected from light and kept in low-binding containers. Some peptides require a carrier protein or cryoprotectant to prevent adsorption and aggregation.
Records should include the lot number, date received, storage temperature, and any handling steps. A log of freeze-thaw cycles and aliquot preparation helps track stability. This documentation supports traceability and quality control.
Removing water reduces hydrolytic and some oxidative degradation. Powder forms are generally more stable for long-term storage than solutions. Stability still depends on peptide sequence, residual moisture, and container conditions.